-
JBCRG-17TR
Translational research for JBCRG-17(Efficacy study of sequential therapy with anthracycline, taxane, and eribulin in patients with HER2-negative locally advanced breast cancer)
- Status
-
Study Closed
- Objectives
-
Identification of a molecular marker to predict the therapeutic effect and marker for "Efficacy study of sequential therapy with anthracycline, taxane, and eribulin in patients with HER2-negative locally advanced breast cancer (JBCRG-17)"
- Subjects
-
Among the patients who participated in the "Efficacy study of sequential therapy with anthracycline, taxane, and eribulin in patients with HER2-negative locally advanced breast cancer (JBCRG-17)"
1)Paraffin block 2)Frozen section 3)Plasma, Serum 4)Frozen whole blood
- Endpoints
-
- Trial Period
-
~November 2024
- Lead Principal Investigator
-
JBCRG-17TR Principal Investigator : Yoshio Miki Japanese Foundation for Cancer Research Department of Genetic Diagonosis Cancer Institute Yosh
- Target Sample Size
-
Patients who agreed to enter JBCRG-17 TR
- Regimen
-
- Source of Funding
-
Japan Breast Cancer Reserch Group, Japanese Foundation for Cancer Research, other
- Conference Presentation
-
- Articles and Publications
-
- UMIN-ID
-
UMIN000009639
- jRCT
-
- Memo
-
- COI Disclosure
-
